NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, announced today its acquisition of Perfectus Biomed Group, a UK founded laboratory, providing customized microbiological services.
“Perfectus Biomed Group is delighted to join NAMSA in its mission to deliver best-in-class global MedTech solutions through its people, expertise and technology. With similar values and expertise to customize solutions for clients across the globe, we are well aligned to achieve future success for both our clients and combined organizations,” stated Sam Westgate, Perfectus Biomed Group CEO. “With the complimentary expertise and resources of NAMSA, we will serve our clients in an even greater capacity and we look forward to joining the world’s leading CRO for full continuum development services,” Westgate concluded.
As the global leader of the medical device testing industry since 1967, NAMSA has amassed a large breadth and depth of therapeutic expertise and knowledge across the continuum of microbiology and in vitro testing services. NAMSA’s world-class testing capabilities include all areas of microbiological sterility, validation and quality assurance solutions in its well-equipped facilities in the U.S. and France.
“NAMSA very much looks forward to expanding its European suite of laboratory services with the addition of Perfectus Biomed Group,” commented Dr. Christophe Berthoux, NAMSA CEO. “Perfectus brings an unmatched level of expertise and depth of knowledge in customized microbiological testing solutions. This know-how and extreme proficiency in microbiological research will help us to further support Clients and continue to provide cutting-edge solutions for medical device testing and research,” Dr. Berthoux concluded.
If you currently have a testing project with us, then rest assured it will not be affected by this announcement. A member of the commercial team will be in touch very soon to answer any questions you may have.
You can be confident that you will continue to receive the same high-quality service you have grown to expect from Perfectus Biomed Group. This transition enables our team access to broader services, expertise and resources.
Our contact details, including email and telephone numbers, won’t be changing. Key contacts within the company will remain the same. If you have any burning questions our commercial team can be contacted at email@example.com or the UK contact number is 01925 737237 and the US contact number is 307 264 1572
We also invite you to follow NAMSA on social media for regular updates, industry insights and more.